Posted by Michael Wonder on 16 Feb 2022
Acadia Pharmaceuticals announces resubmission of supplemental new drug application to U.S. FDA for Nuplazid (pimavanserin) to treat Alzheimer’s disease psychosis
16 February 2022 - Acadia Pharmaceuticals announced today that it has resubmitted its supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis to the U.S. FDA.
This resubmission is in response to the FDA’s 2 April 2021 complete response letter to the supplemental new drug application originally submitted for a proposed indication for pimavanserin for the treatment of dementia-related psychosis.
